| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 02/27/2007 | US7182959 Preparing powder consisting of active substance and all other ingredients of solid dosage form, dispensing solvent solution or dispersion in mold, putting compacted powder on top of liquid in mold, desolventizing |
| 02/27/2007 | US7182958 With oral bioavailability; tadalafil; erectile dysfunction |
| 02/27/2007 | US7182957 Combination of chitosan and second polymer that are not covalently or ionically crosslinked, prepared by dissolving both polymers in an acidic aqueous solution, dehydrating and recovering |
| 02/27/2007 | US7182956 Entrapping in phosphatidylcholine component; room temperature transdermal delivery system; long shelf life |
| 02/27/2007 | US7182951 for hybrid corn seeds; having novel polymeric coatings containing fungicides and optionally insecticides |
| 02/27/2007 | US7182950 Nano-sized self-assembled liquid dilutable vehicles |
| 02/27/2007 | US7182948 Topical veterinary compositions and methods for the treatment and prevention of infection |
| 02/27/2007 | US7182934 Contrast agents |
| 02/27/2007 | US7182933 Biomolecule carrier bearing molecules that bind to a cellular adhesion molecule expressed on endothelial cell |
| 02/27/2007 | US7182199 Systems, methods and apparatuses for manufacturing dosage forms |
| 02/27/2007 | CA2256410C Stable pharmaceutical composition of bdnf |
| 02/27/2007 | CA2240281C Modified release oral pharmaceutical composition containing 5-asa and method for the treatment of bowel diseases |
| 02/27/2007 | CA2158689C Medical devices containing triggerable disintegration agents |
| 02/22/2007 | WO2007022494A2 Multi-drug ligand conjugates |
| 02/22/2007 | WO2007022493A2 Ligand conjugates of vinca alkaloids, analogs, and derivatives |
| 02/22/2007 | WO2007022263A1 Fluorogenic probes for medium chain acyl-coa dehydrogenase ( mcad ) |
| 02/22/2007 | WO2007022255A2 Pharmaceutical formulations for sustained release |
| 02/22/2007 | WO2007022254A2 Pharmaceutical formulations for sustained drug delivery |
| 02/22/2007 | WO2007022239A2 Pharmaceutical formulations for sustained drug delivery |
| 02/22/2007 | WO2007022165A2 Factor xa inhibitor inclusion complex with cyclodextrin |
| 02/22/2007 | WO2007022090A2 Topical delivery with a carrier fluid |
| 02/22/2007 | WO2007022070A2 Modified fc molecules |
| 02/22/2007 | WO2007021970A2 Stable pharmaceutical formulations and methods of use thereof |
| 02/22/2007 | WO2007021073A1 Pharmaceutical formulation with high stability and dissolution and manufacturing process |
| 02/22/2007 | WO2007021020A1 Capsinoid containing composition |
| 02/22/2007 | WO2007020893A1 Water-soluble metal alcoholate derivative, process for production of the derivative, and solid gelatinous agent for external application comprising the derivative |
| 02/22/2007 | WO2007020871A1 Technique for stabilization of yw753 reparation |
| 02/22/2007 | WO2007020349A1 Oil-in-water-type emulsion for topical application in dermatology |
| 02/22/2007 | WO2007020195A2 Peg-ifn alpha and ribavirin for hbv treatment |
| 02/22/2007 | WO2007020085A2 Compositions containing taxane derivatives for intravenous injection |
| 02/22/2007 | WO2007020060A1 Cationic polymer for transporting nucleic acids in cells |
| 02/22/2007 | WO2007019882A1 Seamless coated spherical filled capsules |
| 02/22/2007 | WO2007019661A1 Supplemental dietary composition for enhancing muscle performance and/or recovery from fatigue |
| 02/22/2007 | WO2006134279A3 Method for solubilizing metronidazole |
| 02/22/2007 | WO2006090365A3 Polysaccharide-oligoamine conjugates as anti-amyloid and anti-viral agents |
| 02/22/2007 | WO2006089007A3 Cyclodextrin-based polymers containing photocleavable linkers for drug delivery |
| 02/22/2007 | WO2006088741A3 Procoagulants based on metal-chelating lipids |
| 02/22/2007 | WO2006071441A3 Antibodies directed to gpnmb and uses thereof |
| 02/22/2007 | WO2006059108A3 ANTI-IL-IRl SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC USES |
| 02/22/2007 | WO2005070466A3 Liposome composition for delivery of therapeutic agents |
| 02/22/2007 | WO2004098491A3 METHOD OF PREVENTING INFECTIONS FROM BIOTERRORISM AGENTS WITH IMMUNOSTIMULATORY CpG OLIGONUCLEOTIDES |
| 02/22/2007 | US20070043119 Pharmaceutical compositions comprising 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders |
| 02/22/2007 | US20070043116 Method for preventing and/or treating neurodegenerative diseases |
| 02/22/2007 | US20070043102 Oral suspension of tegaserod |
| 02/22/2007 | US20070042999 Phosphate derivatives of pharmaceutical products |
| 02/22/2007 | US20070042994 Pharmaceutical compositions comprising peranhydrocyclodextrin |
| 02/22/2007 | US20070042955 Abuse-resistant amphetamine prodrugs |
| 02/22/2007 | US20070042943 Cyclosporin active, fatty acid triglyceride, glycerol fatty acid partial ester or propylene glycol or sorbitol complete or partial ester, preferably, and a tenside having an HLB of at least 10; immunosuppressant, anti inflammatory, anti parasitic |
| 02/22/2007 | US20070042942 Glycopeptide carboxy-saccharide derivatives |
| 02/22/2007 | US20070042447 Use of anti-ferritin monoclonal antibodies in the treatment of some cancers (divisional) |
| 02/22/2007 | US20070042432 Method of diagnosis and treatment |
| 02/22/2007 | US20070042046 Methods for the treatment of cancer |
| 02/22/2007 | US20070042045 Multilayer dosage form comprising a matrix that influences release of a modulatory substance |
| 02/22/2007 | US20070042035 applying capsule anti-sticking agent, enzymatically decomposed lecithin, on surface; improved water activity, disintegration property |
| 02/22/2007 | US20070042033 Pantoprazole multiparticulate formulations |
| 02/22/2007 | US20070042032 Self forming, thermodynamically stable liposomes and their applications |
| 02/22/2007 | US20070042030 Preparation for the application of agents in mini-droplets |
| 02/22/2007 | US20070042028 Plaster causing reduced skin irritation |
| 02/22/2007 | US20070042022 Liquid formulations of ractopamine |
| 02/22/2007 | US20070042021 To provide macro-nutrients and micro-nutrient and which prevents and/or alleviates mucosal damage, good-tasting, promotes weight gain; casein and whey proteins, TGF- beta and free glutamine |
| 02/22/2007 | US20070042020 Composition for the treatment of dysfunctional energy metabolism syndrome |
| 02/22/2007 | US20070042019 Method of treating or preventing chronic wounds and a complete nutritional composition comprising glycine and/or leucine for use therein |
| 02/22/2007 | US20070042006 Stable carprofen composition |
| 02/22/2007 | US20070042005 Pharmaceutical composition comprising fungal cell or fragment thereof |
| 02/22/2007 | US20070041987 Fragments or polymers of albumin with tunable vascular residence time for use in therapeutic delivery and vaccine development |
| 02/22/2007 | US20070041968 Methods of inducing an immune response |
| 02/22/2007 | US20070041967 Igg fc fragment for a drug carrier and method for the preparation thereof |
| 02/22/2007 | US20070041939 Modified cytokines for use in cancer therapy |
| 02/22/2007 | US20070041938 Stable aqueous solutions of granulocyte macrophage colony-stimulating factor |
| 02/22/2007 | US20070041932 Conjugate for gene transfer comprising oligonucleotide and hydrophilic polymer, polyelectrolyte complex micelles formed from the conjugate, and methods for preparation thereof |
| 02/22/2007 | US20070041916 Preparation containing diol |
| 02/22/2007 | US20070041904 Peptides whose uptake by cells is controllable |
| 02/22/2007 | US20070041866 Aqueous solution of olanexidine, method of preparing the aqueous solution, and disinfectant |
| 02/22/2007 | DE102005039511A1 Verwendung von quaternären Polysiloxanen in Reinigungs- und Pflegemitteln Use of quaternary polysiloxanes in cleaning and maintenance products |
| 02/22/2007 | DE102005033943A1 Nicht-ausspuckbarer, oraler, schnell-zerfallender Film für ein Neuroleptikum Non-ausspuckbarer, oral, fast-disintegrating film for a neuroleptic |
| 02/22/2007 | CA2619214A1 Factor xa inhibitor inclusion complex with cyclodextrin |
| 02/22/2007 | CA2618993A1 Topical delivery with a carrier fluid |
| 02/22/2007 | CA2618439A1 Technique for stabilization of yw753 reparation |
| 02/22/2007 | CA2617963A1 Oil-in-water-type emulsion for topical application in dermatology |
| 02/22/2007 | CA2617958A1 Peg-ifn alpha and ribavirin for hbv treatment |
| 02/22/2007 | CA2617660A1 Multi-drug ligand conjugates |
| 02/22/2007 | CA2617109A1 Modified fc molecules |
| 02/21/2007 | EP1754712A2 Transcobalamin binding conjugates useful for treating abnormal cellular proliferation |
| 02/21/2007 | EP1754491A1 Ophthalmic percutaneously absorbed preparation containing muscarinic receptor agonist |
| 02/21/2007 | EP1754482A1 Use of an ascomycin for the treatment of blepharitis |
| 02/21/2007 | EP1754480A2 Compositions comprising phospholipase c inhibitors and methods for enhancing paracellular permeability across epithelial and endothelial barriers |
| 02/21/2007 | EP1754479A1 Capsule stable against mastication |
| 02/21/2007 | EP1754470A1 Fat-soluble drug composition |
| 02/21/2007 | EP1754469A1 Injectable suspensions having improved injectability properties |
| 02/21/2007 | EP1753803A2 Polypeptides with the capacity to entrap drugs and release them in a controlled way |
| 02/21/2007 | EP1753787A1 Method of covalently linking hyaluronan and chitosan |
| 02/21/2007 | EP1753781A1 Peptides or peptidic conjugate derivatives of msh and the use thereof for cosmetically fighting against canities |
| 02/21/2007 | EP1753779A2 Interferon-alpha polypeptides and conjugates |
| 02/21/2007 | EP1753478A1 Medical device comprising a biologically active agent |
| 02/21/2007 | EP1753463A2 Antibody drug conjugates and methods |
| 02/21/2007 | EP1753462A2 Process for the preparation of doxorubicin conjugates with lactosaminated human albumin and the obtained conjugates |
| 02/21/2007 | EP1753461A1 Stabilized compositions comprising a therapeutically active agent, citric acid or a conjugated base and chlorine dioxide |
| 02/21/2007 | EP1753438A2 New hydroxapatite calcium phosphates, their method of preparation and their applications |
| 02/21/2007 | EP1753436A2 Anhydrous pharmaceutical composition associating a siliconated agent and solubilised active principle |
| 02/21/2007 | EP1753434A2 Enhanced bimatoprost ophthalmic solution |